Business Wire

XPENG-INC.

29.10.2020 13:02:09 CET | Business Wire | Press release

Share
XPeng Unveils Cutting Edge Features at 2020 Tech Day

XPeng Inc. (“XPeng” or the “Company”, NYSE: XPEV), a leading Chinese smart electric vehicle (“Smart EV”) company, this week released its 2nd Smart Car Operations Report, following its 2nd annual Tech Day where the company unveiled its newly developed cutting edge autonomous driving and in-car smart features.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005643/en/

“2020 to 2022 is a period of gaining significant momentum for the Smart EV sector which will rapidly accelerate from 2023 to 2025 and a create massive disruption to traditional ICE vehicles,” said He Xiaopeng, Chairman & CEO of XPeng.

“End-to-end R&D, data-driven capabilities and fast growth are three initiatives needed for a company to gain long-term competitive advantages and dominant market share,” Chairman He added.

At its 2nd Tech Day, XPeng launched 18 firmware OTA updates, adding 82 new features to its vehicles. The voice assistant’s average monthly utilization rate reached 99.74% and in-car navigation utilization rate achieved 92.54%, according to XPeng’s 2020 Smart Car Operations Report.

XPeng’s autonomous driving system XPILOT 3.0, planned for release in the first quarter of 2021, will provide Navigation Guided Pilot (NGP) for highways and memory auto parking for carparks. These new features address some of the major challenges for drivers in China.

Navigation Guided Pilot (NGP)

Built on XPILOT 3.0, the NGP highway solution enables autonomous driving from point A to point B. The solution will be available on all of China’s major highways with high-precision digital maps and will be the most advanced navigation guided autonomous driving system for production models in China.

The NGP system incorporates driving scenarios specific to China such as traffic cone recognition and avoidance, large truck avoidance, night overtaking reminders, faulty vehicle avoidance, and vehicle follow on congested roads. It can also handle adverse weather conditions, complex roads and locations without GPS signals.

The solution will be the only 360° dual-perception system in the industry with optimal identification of automobile surroundings with the most powerful positioning capabilities in production.

Memory Auto Parking

The XPILOT 3.0 will feature a Memory Parking functionality for parking lots. This feature will recognize side-front parking spaces and cover “the last mile” of parking with the ability to avoid obstacles, plan routes and park with extreme precision. The feature is the world's first auto parking system for production vehicles that does not require any car park modifications.

“Our core competitive advantage is our end-to-end in-house developed software for autonomous driving. In the past few years, we have developed a full range of self-developed R&D and implemented these advanced technologies into our models. There are only two auto makers in the world that have end-to-end autonomous driving capabilities and XPeng is one of them,” said XinZhou Wu, Vice President of Autonomous Driving at XPeng.

World’s first All Voice In-car System

XPeng also introduced another update of its Xmart OS operating system with the world’s first All Voice In-car System, able to deliver the majority of in-car functions. The updated system is the world’s first in-car voice system that responds to continuous driver-vehicle dialogues and is able to execute 10 voice commands every 25 seconds.

“Driver-vehicle interaction technology has evolved from physical buttons to touch screens, to today’s voice commands,” said Ji YU, Vice President of Internet at XPeng.

Xmart OS is now the world’s first open-end vehicle hardware system which allows third-party applications to access vehicle status and data to produce tailor-made infotainment. It also has a unique programmable smart lighting system where users can personalize its lighting effects in the future.

Smart Car by Numbers - 2020 Xpeng Operations Report*

XPeng’s 2nd annual Smart Car Operations Report is based on data from XPeng vehicles from Jan 1, 2020 to Sep 30, 2020. The report illustrates the Smart Cars’ most appealing aspects and how customers value smart features.

  • Firmware OTA launched - 18 times in the past 20 months
  • New features added - 82 items
  • Voice assistant monthly average utilization rate - 99.74%
  • In-car navigation utilization rate - 92.54%

Intelligence Makes Driving Easier

Driving range

  • Longest distance driven by a single vehicle - 3,784 km
  • Accumulative monthly mileage driven by all users - 30,300,000 km

Auto Parking

  • Average monthly obstacle avoidance - 9,585 times
  • Average monthly auto parking - 88,000 times
  • Average time taken for auto parking - 32.3 seconds

ACC (Adaptive Cruise Control)

  • Utilization rate/month – 65.59%
  • Average distance driven/month – 2,286,000 km
  • Distance driven/car/day – 24.6 km

LCC (Lane Centering Control)

  • Utilization rate/month – 42.48%
  • Distance driven/month – 1,127,000 km
  • Distance driven/car/day – 21.7 km

Intelligence Makes Interaction Easier

  • Voice Assistant “Xiao P” total activation - 17,910,000 times
  • Intelligent recommendations provided - 4,484,000 items
  • Intelligent navigation routes recommended by voice assistant - 19,170,000 routes

* Data provided by Xpeng Lab based on data from all Xpeng vehicles from 1 January 2020 to 31 September 2020.

About XPeng

XPeng Inc. is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers in China. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrification/electronic architecture. XPeng is headquartered in Guangzhou, China, with offices in Beijing, Shanghai, Silicon Valley, and San Diego. The Company’s Smart EVs are manufactured at plants in Zhaoqing and Zhengzhou, located in Guangdong and Henan provinces, respectively. For more information, please visit https://en.xiaopeng.com .

Social Media:

https://www.facebook.com/XpengMotorsGlobal/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye